After positive early data, Pfizer, BioNTech CEOs sound off on coronavirus vaccine timelines
On the heels of early positive COVID-19 vaccine data, the CEOs at BioNTech and Pfizer are gearing up for a late-stage trial and talking up potential approvals later this year. In separate interviews this week, Pfizer CEO Albert Bourla and BioNTech CEO Ugur Sahin said their mRNA vaccine candidate could be ready to submit to regulators in the fall or winter, respectively, pending success in… Read More »
